Dutch biotech Crucell seeks further acquisitions but may be a target for takeover by a larger company, CEO Ronald Brus said. Crucell, which has a market value of about $1 billion, is under no pressure to purchase firms but is ready for opportunities, especially because some competitors' cash is dwindling, Brus said.

Related Summaries